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Abstract
Oxatomide at therapeutic doses generates occasionally drowsiness in children. When administered at toxic doses,
however oxatomide may induce long lasting impaired consciousness. We now report a case of severe long lasting
impaired consciousness induced by therapeutic doses of oxatomide occurring in a child affected by acute
gastroenteritis. The clinical symptoms, the pharmacogenetic tests of polymorphisms in cytochrome P450
metabolizing enzymes (CYPs) and the clinical and laboratory analyses indicate that the enhanced drug sedative
effect is likely due to an acute, yet mild, inflammatory state of the patient. These findings highlight the importance
of assessing common, not serious inflammatory states when oxatomide is prescribed in paediatric patients.
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Background
Oxatomide is a H1-histamine receptor antagonist effec-
tive in treatment of allergic rhinitis, urticaria, pruritus
dermatitis, eczema dermatitis, bronchial asthma and
conjunctivitis. The drug inhibits the secretion of several
mediators of inflammation from human basophils and
mast cells [1]. Studies in neutrophils have also shown
that it inhibits arachidonic acid mobilization, and the
synthesis of leukotriene B4 and platelet-activating factor,
possibly by reducing the activities of cytosolic phospho-
lipase A2 [1]. Studies in human liver microsomes [2]
have shown that oxatomide is mainly metabolized by
cytochromes 3A4 (CYP3A4) and 2D6 (CYP2D6), two
enzymes encoded by highly polymorphic genes [3,4]
Whereas at toxic dosages oxatomide may cause coma
and long-lasting impaired consciousness, it is generally
well tolerated at therapeutic dosage, although slight
drowsiness, similarly to other H1-histamine receptor
antagonists, may occur in approximately 50% of the
patients [5]. To date only one study reported the occur-
rence of long-lasting impaired consciousness in paedia-
tric patients at therapeutic oxatomide dosages. No
pathogenic causes were described for such an effect [6].
Case presentation
A 3 year-old Caucasian male, weighing 13.2 Kg, treated
for conjunctivitis with oxatomide (TINSET
® -d r o p s
2.5%) at therapeutic doses (14 mg/day for 2 days)
experienced at home abdominal pains, pallor, trouble
speaking followed by a serious long-lasting impaired
consciousness two days after oxatomide treatment. The
parents also reported muscular hypotonia. After 2 days
the parents accessed the Emergency Department where
the child was immediately admitted. The child had no
history of recent trauma, seizures and neurologic dis-
eases and was receiving no other drug treatment. The
child was affected by acute gastroenteritis.
After admission to the Emergency Department oxato-
mide was withdrawn. Nonetheless, the patient’ss t a t eo f
impaired consciusness persisted with very low response
to pain stimulation tests and a Glasgow coma score of
4, which led to immediate recovery to the Paediatric
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were taken.
The brain Computed Tomography Scan was negative
with normal deep tendon reflexes. The results of blood
gas analysis, serum electrolytes levels, hepatic and renal
tests were normal. The cerebrospinal fluid was clear and
colourless with normal protein levels and a negative
cytological test. Likewise negative in the cerebrospinal
fluid were all virological tests (Herpes Simplex1 and 2,
Varicella Zooster and enteroviruses), and tests for
mycetes, M. tuberculosis and Gram positive and negative
bacteria. The urinalysis excluded infections by Strepto-
coccus pneumoniae, Haemophylus influenzae, Neisseria
meningitis and Streptococcus agalactiae.M o r e o v e r ,t h e
urinalysis was negative for barbiturates, benzodiazepines,
opiates, cocaine, amphetamine, methamphetamine and
antidepressant drugs that could have increased the seda-
tive properties of oxatomide. The stool cultures for Sal-
monella tiphymurium, Shigella, Campylobacter were
also negative. The results of haematochemical tests
showed elevated leukocytes (12.77*10e3/uL) and a CRP
value of 0.47 mg/dL (physiologic range < 0.25 mg/dL)
while the white blood count revealed a decreased num-
ber of neutrophils (39.5%); these results are compatible
with a slight clinical pictures of inflammation due to an
intercurrent gastroenteritis.
The patient was hospitalized in the Paediatric Unit
and forty-eight hours after oxatomide withdrawal, the
patient’s conditions although asthenia and headache per-
sisted, remitting completely in the days.
Based on the clinical data thep h y s i c i a n se x c l u d e da n
acute encephalitis and correlated the symptoms to an
oxatomide adverse effect. Since the patient was treated
with a standard dose of oxatomide as the only therapy it
was initially hypothesized that the observed over-
response to oxatomide was due to a inherited defect in
the activity of cytochromes CYP3A4 and/or CYP2D6,
ultimately resulting in impaired drug metabolism and
drug accumulation. The patient was therefore screened
for the main allelic variants of CYP3A4 (CYP3A4*1B)
and CYP2D6 (namely CYP2D6*3, *4, *5 and *6). How-
ever, none of the above mentioned polymorphisms were
detected by pyrosequencing analysis performed using
the diagnostic kits Diatech Explera according to the
manufacturer’s instructions.
The Naranjo adverse drug reaction probability scale
[7] identified the relationship between the patient’s
development of ADR and the drug as “possible”.
The only published article of a long-lasting impaired
consciousness after therapeutic oxatomide treatment
was in 1986 [6], when Van Daele et al. reported six
cases of acute dystonic reactions and long-lasting
impaired consciousness, occurring 30-60 after hours the
start of treatment, in patients treated with “more or less
normal” doses of oxatomide. The children showed
altered consciousness varying from lethargy and somno-
lence to frank encephalitis.
The causes for those episodes of acute toxicity to oxa-
tomide were not known. Our results from pharmacoge-
netic screening exclude for our patient inherited defects
in the ability of metabolizing oxatomide. The age-depen-
dent variability in the activity of some CYP may also be
excluded. CYP3A4 activity, weak in the foetus and after
birth, becomes very similar to that of an adult within
the first years of life; likewise, CYP2D6 activity in infants
a n dc h i l d r e nu pt of i v ey e a r so fa g ei sa b o v et w o - t h i r d
of the average adult levels [8]. We could not carry out a
pharmacokinetic profile of oxatomide serum levels.
Thus, the possibility that changes in expression of wild
type CYP may have contributed to the observed ADR by
oxatomide cannot be excluded.
Clinical and preclinical studies indeed show that
increases in proinflammatory molecules such as inter-
leukins (IL-1, IL-6, IL-8), tumour necrosis factor-a
(TNF-a) and interferon-g is associated with downregula-
tion of expression and activity of several cytochromes
including CYP3A4 and CYP2D6 [9]. Indeed IL-6, IL-8
and TNF-a concentrations in patients with gastroenteri-
tis are significantly increased [10,11]. It is therefore con-
ceivable that the release of these proinflammatory
molecules has decreased CYP activities, eventually lead-
ing to increased oxatomide concentrations in the plasma
of our patient, thus contributing to the observed neuro-
logical ADR.
Conclusions
Based on our clinical observations and the data from the
literature we conclude that clinicians and researchers
must be extremely careful to assess common, not ser-
ious inflammatory states when prescribing oxatomide, in
order to prevent serious neurological ADRs of this drug
and improve safety in the paediatric clinical practice.
The possibility to prescribe non sedating anti-histamine
drugs for allergy should be considered.
Consent
Written informed consent was obtained from the
patients’ guardians for publication of this report and any
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